Comparative Pharmacology
Head-to-head clinical analysis: ALTRENO versus TRETINOIN MICROSPHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTRENO versus TRETINOIN MICROSPHERE.
ALTRENO vs TRETINOIN MICROSPHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
Tretinoin microsphere is a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ), modulating gene expression involved in cell proliferation, differentiation, and inflammation. It normalizes follicular keratinization, reduces microcomedone formation, and increases epidermal turnover.
ALTRENO is not a recognized drug. No data available.
Apply a pea-sized amount (approximately 0.5 g) topically once daily at bedtime to dry skin.
None Documented
None Documented
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Terminal elimination half-life approximately 0.5–2 hours in terminal phase; longer terminal phase (10–20 hours) observed for 13-cis-retinoic acid metabolite.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Primarily hepatic metabolism via CYP450 isoforms to polar metabolites; renal excretion accounts for <1% unchanged; biliary/fecal elimination of metabolites is significant (approximately 30-60%).
Category C
Category D/X
Retinoid
Retinoid